Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.110
+0.040 (3.74%)
Mar 9, 2026, 3:31 PM EDT - Market open

Estrella Immunopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Sep '25 Dec '24 Jun '24 Jun '23 Jun '22 Jun '21
Selling, General & Admin
3.943.143.20.660.30.28
Research & Development
9.565.724.1110.451.390.46
Operating Expenses
13.518.857.3111.111.690.73
Operating Income
-13.51-8.85-7.31-11.11-1.69-0.73
Pretax Income
-13.51-8.85-7.31-11.11-1.69-0.73
Income Tax Expense
-000---
Net Income
-13.51-8.85-7.31-11.11-1.69-0.73
Preferred Dividends & Other Adjustments
-----0.61-
Net Income to Common
-13.51-8.85-7.31-11.11-1.07-0.73
Shares Outstanding (Basic)
3737270--
Shares Outstanding (Diluted)
3737270--
Shares Change (YoY)
2.36%34.73%8764.81%---
EPS (Basic)
-0.37-0.24-0.27-36.35--
EPS (Diluted)
-0.37-0.24-0.27-36.35--
EBIT
-13.51-8.85-7.31-11.11-1.69-0.73
Source: S&P Capital IQ. Standard template. Financial Sources.